Komori
Seikagaku (4548) · InitiativeFirst stated

Domestic Phase III Development of Gel-One and Joint Development and Exclusive Sales Partnership with ONO PHARMACEUTICAL CO.,LTD.

First written in FY2026-H1. . Latest entry: FY2026-H1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Gel-One domestic Phase III development and joint development and sales partnership with Ono PharmaceuticalA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026-H1First statedAnnual report

    「In February 2025, the company began Phase III clinical trials for knee osteoarthritis and hip osteoarthritis, respectively. In August 2025, it also entered into a formal agreement with Ono Pharmaceutical Co., Ltd. covering joint development and a sales partnership. Joint development and exclusive domestic sales rights for Gel-One, a treatment for osteoarthritis Contract term: From the contract date until the anniversary of the 10th anniversary of the product launch, with renewal every 2 years thereafter」

    For Gel-One, the company began domestic Phase III clinical trials for knee and hip osteoarthritis in February 2025 and formally entered into a joint development and exclusive domestic sales agreement with Ono Pharmaceutical Co., Ltd. in August of the same year. The contract runs until the 10th anniversary of the product launch and is renewed every 2 years thereafter.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Seikagaku yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Domestic Phase III Development of Gel-One and Joint Development and Exclusive Sales Partnership with ONO PHARMACEUTICAL CO.,LTD. | SEIKAGAKU CORPORATION (4548) | Komori